Fucosylated Chondroitin Sulfate from Isostichopus Badionotus Alleviates Metabolic Syndromes and Gut Microbiota Dysbiosis Induced by High-Fat and High-Fructose Diet.

Shan Li,Junhui Li,Guizhu Mao,Tiantian Wu,Dingbo Lin,Yaqin Hu,Xingqian Ye,Ding Tian,Wengang Chai,Robert J. Linhardt,Shiguo Chen
DOI: https://doi.org/10.1016/j.ijbiomac.2018.11.167
IF: 8.2
2018-01-01
International Journal of Biological Macromolecules
Abstract:Fucosylated chondroitin sulfate from Isostichopus badionotus (fCS-Ib) is a kind of sulfated polysaccharides with well-repeated structure. In our former publications, fCS-Ib has been reported to be a functional food ingredient with hypoglycemic and antilipemic activities. However, there is no systematic study to investigate the effects of fCS-Ib on metabolic syndromes. In the present study, C57BL/6 mice fed on a high-fat and high sucrose diet (HFSD) for 6 weeks was used to cause metabolic syndromes. The final results showed that fCS-Ib alleviated obesity, hyperlipidemia, hyperglycemia, inflammation, liver steatosis, and adipocyte hypertrophy caused by HFSD. Meanwhile, fCS-Ib showed powerful effects on moderating gut microbiota dysbiosis in the HFSD-fed mice. Supplement of fCS-Ib could reduce ratio of Firmicutes to Bacteroidetes by decreasing abundance of Lachnospiraceae and Allobaculum while increasing abundance of Porphyromonadaceae, Barnesiella, and Bacteroides. Our results showed that fCS-Ib could be further developed as a potential pharmaceutical agent to prevent metabolic syndromes and gut microbiota dysbiosis.
What problem does this paper attempt to address?